^
    Back
    Association details:
    Biomarker:PALB2 mutation
    Cancer:Melanoma
    Drug Class:CTLA4 inhibitor
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    PALB2 mutation as a predictive biomarker for immunotherapy in patients with advanced melanoma: Results from (a pooled analysis of) five multicenter, randomized clinical trials

    Published date:
    05/19/2021
    Excerpt:
    A subgroup analysis of CTLA4 inhibitor treatment found that PALB2mut was associated with better ORR (50% versus 18.3%, P = 0.016) on immunotherapy...PALB2 may serve as a positive predictor of immunotherapy (CTLA4 inhibitor therapy) in patients with advanced melanoma...
    DOI:
    10.1200/JCO.2021.39.15_suppl.e21537